scholarly journals Effects of Arsenic (+3 Oxidation State) Methyltransferase Gene Polymorphisms and Expression on Bladder Cancer: Evidence from a Systematic Review, Meta-analysis and TCGA Dataset

2020 ◽  
Vol 177 (1) ◽  
pp. 27-40
Author(s):  
Yuxuan Song ◽  
Donghui Jin ◽  
Jingyi Chen ◽  
Wanfeng Liang ◽  
Xiaoqiang Liu
Keyword(s):  
Bladder Cancer ◽  
Survival Time ◽  
Oxidation State ◽  
Meta Analysis ◽  
The Cancer Genome Atlas ◽  
Related Factor ◽  
Genotype Distribution ◽  
Case Control Studies ◽  
Poor Overall Survival ◽  
Allele Distribution

Abstract Inorganic arsenic (iAs) is a recognized environment-related factor for bladder cancer (BCa). Arsenic (+3 oxidation state) methyltransferase (AS3MT) gene might influence BCa by regulating iAs metabolism. The aim of the present study was to explore whether AS3MT polymorphisms could affect BCa susceptibility. We systematically reviewed eligible case-control studies about AS3MT polymorphisms and BCa and to further compare the genotype distribution and allele distribution between BCa patients and controls by meta-analysis for humans. Besides, to clarify the effects of AS3MT expression on BCa clinical outcomes and survival time, we also conducted a series of analyses based on The Cancer Genome Atlas dataset. Databases were systematically retrieved and we applied Stata software to perform meta-analysis. The registration of this study protocol is at PROSPERO and ID is CRD42019133947. Five articles were recruited and pooled results demonstrated that rs3740393 and rs11191438 polymorphisms were related to BCa risk in overall population (p < .05) in the overall population. In addition, GG and GC genotypes in rs3740393 and GG genotype in rs11191438 might be the susceptibility genotypes for BCa. Results based on 168 BCa samples from TGCA indicated that patients with higher expression of AS3MT had poor overall survival time and AS3MT expression is an independent indicator for BCa survival. This study identified that AS3MT polymorphisms could affect BCa risk and AS3MT expression was pivotal in prognosis of BCa.

The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: a Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Kai Gan ◽  
Yue Gao ◽  
KuangZheng Liu ◽  
Bin Xu ◽  
Ming Chen
Keyword(s):  
Bladder Cancer ◽  
Clinical Significance ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Growth Factor Receptor ◽  
Tumor Stage ◽  
The Cancer Genome Atlas ◽  
Her2 Expression ◽  
Large Tumor ◽  
Normal Tissues

Abstract Objective: Human Epidermal Growth Factor Receptor 2 (HER2) is highly expressed in a variety of tumors and associated with patients’ prognosis, but its role in bladder cancer remains unclear. We conducted this meta-analysis to explore the clinical significance and prognostic value of HER2 in bladder cancer and its potentiality as an immunotherapy target.Methods: PubMed was searched for studies published between January 1, 2000 and January 1, 2020. The odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were used to investigate the relationship between HER2 and bladder cancer. UALCAN website was used to obtain TCGA (The cancer genome atlas) database.Results: Our study includes 14 articles, 1398 patients. HER2 expression was significantly higher in bladder cancer than in normal tissues. Our meta-analysis results did not reveal any effect of gender on the expression of HER2 levels in bladder cancer patients. However, HER2 expression in male patients was significantly higher than that in women according to TCGA databases. HER2 expression was also associated with carcinoma in situ, multifocal tumors, large tumor size, high tumor stage and grade, lymph node metastases, risk of recurrence and progression, low recurrence-free survival (RFS) rate. HER2 expression status had no effect on overall survival.Conclusions: Our meta-analysis showed that HER2 expression was related to pathological malignancy and poor prognosis in bladder cancer which indicated that it could be used as an effective biomarker and therapeutic target.

scholarly journals TP73-AS1 as a Predictor of Clinicopathological Parameters and Prognosis in Human Malignancies: A Meta and Bioinformatics Analysis

2021 ◽  
Author(s):  
Caizhi Chen ◽  
Jingjing Wang ◽  
Yeqian Feng ◽  
Ye Liang ◽  
Yan Huang ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
The Cancer Genome Atlas ◽  
Prognostic Indicators ◽  
Cochrane Library ◽  
Clinicopathological Parameters ◽  
Oncogenic Signaling ◽  
Poor Overall Survival ◽  
The Cochrane Library

Abstract Background: LncRNA TP73-AS1 is dysregulated in various tumors but the correlation between its expression and clinicopathological parameters and/or prognoses in cancer patients is inconclusive. Here, we performed a meta-analysis to evaluate the prognostic value of lncRNA TP73-AS1 for malignancies.Methods: We systematically searched four online databases including PubMed, the Web of Science, Embase, and the Cochrane Library for eligible articles published up to June 29/2020. Odds ratios (ORs) and Pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the association of TP73-AS1 expression with prognostic and clinicopathological parameters. We further validated TP73-AS1 expression in various malignancies and its potential prognostic value using the GEPIA online database. We predicted potential biological processes and relevant signal mechanisms through the public databases.Results: A total of 26 studies including 1770 patients were analyzed to evaluate the relationship between TP73-AS1 expression, clinicopathological features and prognostic indicators. The results indicated that TP73-AS1 expression markedly correlates with TNM stage, tumor size, lymph node metastasis and distant metastasis. No correlation with age, gender or differentiation was observed. TP73-AS1 overexpression was a biomarker of poor Overall survival (OS) and Disease-Free-Survival (DFS). Dysregulated TP73-AS1 expression and its prognostic value in various cancers was validated based on The Cancer Genome Atlas (TCGA). Further biological function predictions indicated that TP73-AS1 was involved in pro-oncogenic signaling.Conclusions: The upregulation of LncRNA TP73-AS1 was related to detrimental clinicopathological parameters and can be considered an indicator of poor prognosis for cancer malignancies.

scholarly journals Identification of RB1 Gene as a Immune-Related Prognostic Signature Based on Tumor Mutation Burdens in Bladder Cancer

2021 ◽  
Author(s):  
Ming Chen ◽  
Hong Cheng ◽  
Tiange Wu ◽  
Zeping Gui ◽  
Ying Gao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Immune Cells ◽  
Immune Cell ◽  
Checkpoint Inhibitors ◽  
Cancer Genome ◽  
Gene Set Enrichment Analysis ◽  
The Cancer Genome Atlas ◽  
Sequencing Data ◽  
Poor Overall Survival ◽  
Mutant Type

Abstract Background: Bladder cancer (BC) is known as the eleventh most common malignant tumor all over the world, for either males or females. Developing effective regimens targeting more promising biomarkers aiming for better prognosis are required. Immune checkpoint inhibitors (ICI) have been demonstrated as a prospective and practical means to resist cancers. Theoretically, adequate infiltration of immune cells indicates more immunotherapy targets and may promise better prognosis.Methods: Full transcriptome data (n=433), clinical information (n=581) and mutation sequencing (n=412) were obtained freely from The Cancer Genome Atlas and independent mutation sequencing data of 101 samples were acquired from International Cancer Genome Consortium. Statistical processing was conducted using R packages with R x64 4.0.2. Gene biologically functional research was performed with gene set enrichment analysis (GSEA) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) database. 22 types of immune cell infiltration were assessed and calculated in 398 samples of BC tumors.Results: Tumor mutation burdens (TMB) of mutant type groups were higher than wild type groups for 19 genes, except for FGFR3 and CREBBP verifying that genomic mutation associates positively with TMB in BC tumor. Kaplan-Meier analysis showed high mutation frequency on RB1 had a negative effect on prognosis of BC patients and RB1 was an independent prognostic factor (p=0.004, HR=1.776) in BC. It was also demonstrated that RB1 mainly participate in singling pathways of cell proliferation and cell cycle. Proportions and correlation of 22 types of immune cells in 433 samples were determined. Immune cells with similar function are inclined to co-exist in tumor microenvironment of BC. Among them, regulatory T cells (Tregs) were detected as a negatively correlated type immune cell to mutation of RB1 that probably increases the incidence of tumor immune escaping in BC.Conclusion: RB1 can be identified as an independent prognostic predictor, and there is a chance for contribution to poor overall survival as the mutation occurs. What's more, mutation of RB1 also functions as a biomarker that represses the infiltration of Tregs, increasing the incidence of tumor immune escaping in BC.

scholarly journals High Vimentin Expression Predicts a Poor Prognosis and Progression in Colorectal Cancer: A Study with Meta-Analysis and TCGA Database

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Le Du ◽  
Jingchuan Li ◽  
Lei Lei ◽  
Hongjuan He ◽  
Erfei Chen ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Univariate Analysis ◽  
Disease Free Survival ◽  
The Cancer Genome Atlas ◽  
Poor Overall Survival ◽  
Vimentin Expression ◽  
Cancer Genome Atlas ◽  
N Stage

The aim of this study was to evaluate the role of vimentin expression in the prognosis and progression of CRC. Meta-analysis was conducted to investigate the correlations between vimentin and prognosis and clinicopathological features in CRC. Literatures were searched by PubMed, Embase, ClinicalKey, CNKI, VIP, and WanFang databases. The Cancer Genome Atlas (TCGA) database was used to assess the association of vimentin expression with survival rate in CRC. Eleven reports with 1969 cases were included in the meta-analysis. The results showed that positive vimentin expression predicted a poor overall survival (OS) in the univariate analysis (HR: 2.087, 95%CI: 1.660-2.625) and multivariate analysis (HR: 1.633, 95%CI: 1.223-2.181). Vimentin overexpression also conferred worse disease-free survival (DFS) in the univariate analysis (HR: 2.069, 95%CI: 1.024-4.179) and multivariate analysis (HR: 2.802, 95%CI: 1.421-5.527). Moreover, upregulated vimentin is related to lymph node metastasis (OR: 2.288, 95%CI: 1.159-4.517), TNM stages (OR: 1.957, 95%CI: 1.333-2.873), and N stage (OR: 2.316, 95%CI: 1.482-3.620). Analysis of TCGA database indicated that elevated vimentin predicated a shorter OS (p=0.033). Our findings reveal that upregulated vimentin contributes to the progression and poor prognosis of CRC. Vimentin may be a prognostic biomarker and therapeutic target in patients with CRC.

Water disinfection by-products and bladder cancer: is there a European specificity? A pooled and meta-analysis of European case-control studies

2011 ◽  
Vol 68 (5) ◽  
pp. 379-385 ◽  
Author(s):  
N. Costet ◽  
C. M. Villanueva ◽  
J. J. K. Jaakkola ◽  
M. Kogevinas ◽  
K. P. Cantor ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Meta Analysis ◽  
Case Control ◽  
Water Disinfection ◽  
Case Control Studies ◽  
By Products

scholarly journals Identification and Validation of a Novel Immune-Related lncRNA Signature for Bladder Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Shan Hua ◽  
Zhiwen Xie ◽  
Wenhao Wang ◽  
Zhong Wan ◽  
Min Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Checkpoint Inhibitors ◽  
Univariate Analysis ◽  
Risk Groups ◽  
The Cancer Genome Atlas ◽  
Receiver Operating Curve ◽  
Multiple Perspectives ◽  
Pathological Characteristics

PurposeWe aimed to construct an immune-related long noncoding ribonucleic acids (irlncRNA) signature to evaluate the prognosis of patients without specific expression level of these irlncRNA.MethodsThe raw transcriptome data were downloaded from The Cancer Genome Atlas (TCGA), irlncRNAs were filtered out using an online immune related gene database and coexpression analysis, differently expressed irlncRNA (DEirlncRNA) pairs were identified by univariate analysis. The areas under curve (AUC) were compared and the Akaike information criterion (AIC) values of receiver operating curve (ROC) was counted, the most optimal model was constructed to divide bladder cancer patients into high- and low-risk groups usingõ the cut-off point of ROC. Then, we evaluated them from multiple perspectives, such as survival time, clinic-pathological characteristics, immune-related cells infiltrating, chemotherapeutics efficacy and immune checkpoint inhibitors.Results14 DEirlncRNA pairs were included in this signature. Patients in high-risk groups demonstrated apparent shorter survival time, more aggressive clinic-pathological characteristics, different immune-related cells infiltrating status, lower chemotherapeutics efficacy.ConclusionThe irlncRNA signature demonstrated a promising prediction value for bladder cancer patients and was important in guiding clinical treatment.

scholarly journals Clinicopathological significance and prognosis of long noncoding RNA SNHG14 expression in human cancers: A Meta-Analysis and bioinformatics analysis

2021 ◽  
Author(s):  
Bin Liu ◽  
Tingting Lu ◽  
Yongfeng Wang ◽  
Yaqiong Chen ◽  
Shixun Ma ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Cox Regression ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Significant Difference ◽  
Pan Cancer

Abstract Background SNGH14 is a recently found long non-coding RNA (lncRNA) with a strong link to cancer. However, it is uncertain if the expression of SNHG14 is linked to the prognosis of individuals with various forms of cancer. We conducted a meta-analysis of the available literature to evaluate the association between SNHG14 and clinicopathological characteristics and patient prognosis Methods The databases PubMed/Medline, Web of Science, Cochrane Library, and Embase were combed for relevant papers published till November 2021. The odds ratio (OR) and 95% confidence interval (CI) were used to analyze dichotomous variables, while the hazard ratio (HR) and 95% CI were employed as a summary statistic for survival outcomes. In addition, the Cancer Genome Atlas TCGA (TCGA) and gene expression omnibus (GEO) database were utilized to investigate SNHG14 differential expression in pan-cancers. Cox regression and Kaplan-Meier analysis were used to investigate the prognostic significance of SNHG14 in pan-cancer. The association between the degree of SNHG14 expression in pan-cancer and immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI) was measured using Spearman correlations. Results A total of 21 studies with 1,080 patients, mainly from China, were included. Our results showed that elevated SNHG14 expression was significantly associated with poor overall survival (OS) (HR = 1.39; 95% CI: 1.06-1.83; P = 0.017). In addition, increased SNHG14 expression was associated with tumor size (OR = 1.60; 95% CI: 1.20-2.14; P = 0.001), TNM staging (OR = 0.54; 95% CI: 0.40-0.71; P <0.001), lymph node metastasis (OR = 1.86; 95% CI: 1.35-2.55; P <0.001), differentiation grade (OR = 1.95; 95% CI: 1.36-2.80; P <0.001), and distant metastasis (OR = 2.44; 95% CI: 1.30 -4.58; P= 0.005). However, there was no significant difference in age (OR = 1.02; 95% CI: 0.77-1.33; P = 0.863) and gender (OR = 0.98; 95% CI: 0.72-1.35; P = 0.915). Conclusion This study revealed that overexpression of SNGH14 is associated with low OS rate and clinicopathological characteristics. SNGH14 can be considered as a new tumor marker that aids in early tumor diagnosis, thus improving the prognosis of patients.

Sign in / Sign up

Export Citation Format

Share Document